-
Alcaraz faces Shelton in blockbuster US Open quarter-final
-
UK PM denounces 'politics of poison' after anti-migrant protests
-
Trump threatens sales in US of Canadian aircraft maker Bombardier
-
Comeback queen Zheng strikes again for US Open quarter-final berth
-
Eiffel Tower closed in row over women removed for Hindu group
-
Third absence for injured Hadjar as Lawson fills in again in Spain
-
Willemse replaces Kolbe for Springboks' All Blacks series decider
-
Far-right victory in Germany draws protesters in Berlin
-
Zheng shocks Swiatek in another incredible US Open comeback
-
CapTLX Launches Institutional Gateway to U.S. Private Markets, Expanding Access to Structured Investment Opportunities
-
Andreeva survives in three sets against Potapova
-
Africa's richest man eyes continent's largest IPO
-
Alleged killers of Australian, US surfers go on trial in Mexico
-
Macron, SKorea leader warn at film summit of AI risks to creativity
-
King Charles classes Harry and Meghan as 'private citizens'
-
'Impressive' Alcaraz has Shelton in sights in US Open quarter-final
-
Bowling coach Noffke says Pakistan's off-field issues are nothing new
-
Noosha Aubel a krize v Postupimi: Jak dlouho je ještě možné tolerovat toto selhání vedení?
-
Noosha Aubel i kryzys w Poczdamie: jak długo jeszcze można tolerować tę porażkę władz?
-
Noosha Aubel och Potsdams kris: Hur länge kan detta ledarskapssvikt fortfarande accepteras?
-
ヌーシャ・オーベルとポツダムの危機:この指導力の欠如は、いつまで容認され続けるのか?
-
Η Noosha Aubel και η κρίση του Πότσνταμ: Για πόσο ακόμα είναι ανεκτή αυτή η διαχειριστική αποτυχία;
-
नूशा ऑबेल और पॉट्सडैम का संकट: नेतृत्व की इस विफलता को और कितना सहन किया जा सकता है?
-
누샤 아우벨과 포츠담의 위기: 이러한 리더십 부재는 얼마나 더 용인될 수 있는가?
-
努莎·奧貝爾與波茨坦的危機:這種領導失職還能容忍多久?
-
نوشا أوبيل وأزمة بوتسدام: إلى متى سيظل هذا الفشل القيادي مقبولاً؟
-
Нуша Аубель і криза в Потсдамі: як довго ще можна миритися з цією неспроможністю керівництва?
-
Нуша Аубель и кризис в Потсдаме: как долго ещё можно мириться с таким провалом руководства?
-
Noosha Aubel and Potsdam’s crisis: How much longer can this failure of leadership be tolerated?
-
England quick Archer in 'good place' after injuries
-
US envoy sees 'movement' toward three-way talks with Russia, Ukraine
-
Robots protest rampant AI in Poland
-
Thousands bid farewell to Bosnian Serb war criminal in Belgrade
-
Rare woman director in Venice sees industry backsliding on gender
-
EU chief announces 200-mn-euro investment package for Greenland
-
France, SKorea warn at film summit of AI risks to creativity
-
Lebanon says Israel conducts wave of deadly strikes
-
Z Traders Introduces New Funding Model Designed to Expand Opportunities in Trading
-
Cipheras Group - Apex AI Fund Deploys 290-Billion-Parameter Proprietary Large Language Model
-
Lebanon says 12 killed in strikes as Israel vows to 'remove threats'
-
Germany's Merz 'shocked' by far-right state win but vows to stay course
-
Volkswagen plant to be converted for Israeli defence group
-
UK finance minister Healey pledges strict fiscal discipline as budget looms
-
Israeli rubble-clearing in Gaza could erase 'atrocity crimes' evidence: UN expert
-
Mbappe embraces Ballon d'Or talk after historic World Cup exploits
-
Scorching summer pushes French wine harvest to new historic low
-
Tech firms rally, with eyes on US inflation update
-
Pietersen joins England coaching team ahead of World Cup
-
Jaguar Land Rover to cut 4,000 jobs as European car sector hits skids
-
Germany's triumphant far-right AfD aims fire at Merz
Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks
LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 8, 2025 / Renovaro Inc. (NASDAQ:RENB) was referenced in a recent RealClearDefense article titled "AI Can Be Used to Develop Biological and Chemical Weapons", which examines the complex challenges posed by artificial intelligence in the context of global security and biodefense.
The full article can be accessed at: https://www.realcleardefense.com/articles/2025/08/07/ai_can_be_used_to_develop_biological_and_chemical_weapons_1127450.html
Renovaro's inclusion reflects its growing role in advancing responsible innovation at the intersection of AI, counter bioterrorism, and national preparedness. The company's strategic focus includes the development of precision neurology platforms and AI-enhanced countermeasures designed to detect, mitigate, and respond to emerging biological threats.
Commenting on the company's recently announced countermeasure initiative, CEO David Weinstein stated:
"We believe the convergence of AI and biotechnology demands not only innovation, but moral clarity. Our countermeasure initiative is designed to anticipate and neutralize biological threats before they escalate - while reinforcing cognitive resilience and operational integrity in those on the front lines. Renovaro is committed to building technologies that protect life and uphold trust."
Renovaro continues to engage with regulators, researchers, and strategic partners to ensure its platforms meet the highest standards of safety, transparency, and ethical deployment. The company views its mention in RealClearDefense as part of a broader recognition of the urgent need for leadership in biodefense innovation.
About Renovaro (NASDAQ: RENB)
Renovaro Inc. (NASDAQ: RENB) is building category-defining AI-driven platforms for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our filings with the SEC for a discussion of these risks.
Contact:
[email protected]
www.renovarogroup.com
SOURCE: Renovaro Biosciences
View the original press release on ACCESS Newswire
P.Martin--AMWN